Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: J Neural Transm (Vienna). 2017 Jan 23;124(5):655–667. doi: 10.1007/s00702-017-1680-4

Figure 2.

Figure 2

Dopamine transporter (DAT) binding following chronic oral methylphenidate treatment (A&C) and abstinence (AB) (B&D). (A) High dose (HD MP) treated rats had increased DAT binding in the middle dorsolateral caudate putamen (mid dl CPu), middle dorsomedial caudate putamen (mid dm CPu), middle ventrolateral caudate putamen (mid vl CPu), middle ventromedial caudate putamen (mid vm CPu), and ventral tail of the caudate putamen (v CPu tail) compared to water treated rats, and in the mid dl CPu, mid dm CPu, mid vl CPu, and mid vm CPu compared to low dose (LD MP) treated rats (p≤0.01 for all). *HD MP vs. water, ∧HD MP vs. LD MP. (B) There were no significant differences in DAT binding between treatment groups in rats euthanized after an abstinence period. (C&D) Autoradiographic images of dopamine transporter binding with [3H] WIN35,428. Images represent brain sections from rats treated with water, low dose methylphenidate (LD MP), and high dose methylphenidate (HD MP) and euthanized immediately following treatment (C) or after an abstinence (AB) period (D). Measures on left show approximate distance from Bregma.